Analyst Price Target is $11.00
▲ +393.27% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Lexaria Bioscience in the last 3 months. The average price target is $11.00, with a high forecast of $12.00 and a low forecast of $10.00. The average price target represents a 393.27% upside from the last price of $2.23.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Lexaria Bioscience.
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Read More
